Results 121 to 130 of about 48,636 (310)

mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting

OncoImmunology, 2018
Chimeric antigen receptor T cells (CAR-Ts) are promising cancer therapeutics. However, since cancer cells can lose the CAR-targeted antigen and avoid destruction, targeting multiple antigens with multiple CARs has been proposed. We illustrate here a less
Jason J. Lohmueller, James D. Ham, Michael Kvorjak, Olivera J. Finn   +3 more
doaj   +1 more source

Diagnostic value of immunohistochemistry staining of Bcl-2, CD34, CD20 and CD3 for distinction between discoid lupus erythematosus and lichen planus in the skin

Indian Journal of Pathology and Microbiology, 2017
Background: Cluster of differentiation (CD) markers is a classification system for monoclonal antibodies against cell surface molecules on leukocytes and antigens from other cells. Aims: The aim of this study is to evaluate immunohistochemical markers in
Mazaher Ramezani, Bita-Sadat Hashemi, Sedigheh Khazaei, Mansour Rezaei, Ali Ebrahimi, Masoud Sadeghi   +5 more
doaj   +1 more source

A Non-Covalent Antibody Complex for the Delivery of anti-cancer drugs [PDF]

, 2019
Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monoclonal antibody (mAb), are traditionally bound in a random way to lysine or cysteine residues, with the final product's heterogeneity having an important ...
Grigoletto, Antonella, Maso, Katia, Monia Montagner, Isabella, Pasut, Gianfranco, Rosato, Antonio, Schiavon, Oddone   +5 more
core   +1 more source

Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells

Haematologica
Our investigation uncovers that nanomolar concentrations of salinomycin, monensin, nigericin, and narasin (a group of potassium/sodium cation carriers) robustly enhance surface expression of CD20 antigen in B-cell-derived tumor cells, including primary malignant cells of chronic lymphocytic leukemia and diffuse large B-cell lymphoma.
Anna Torun, Aleksandra Zdanowicz, Nina Miazek-Zapala, Piotr Zapala, Bhaskar Pradhan, Marta Jedrzejczyk, Andrzej Ciechanowicz, Zofia Pilch, Marcin Skorzynski, Mikołaj Słabicki, Grzegorz Rymkiewicz, Joanna Barankiewicz, Claudio Martines, Luca Laurenti, Marta Struga, Magdalena Winiarska, Jakub Golab, Magdalena Kucia, Mariusz Z. Ratajczak, Adam Huczynski, Dinis P. Calado, Dimitar G. Efremov, Abdessamad Zerrouqi, Beata Pyrzynska   +23 more
openaire   +3 more sources

Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors

Interdisciplinary Medicine, EarlyView.
Napabucasin reduces liver metastases by reprogramming the hepatic microenvironment. It induces hepatocyte secretion of CCL21 via c‐Fos activation, recruiting lymphocytes and converting “cold” metastases into immunologically “hot” tumors. This effect is liver‐specific and independent of cancer cells.
Qiongqiong Wang, Jiaqi Zhou, Hang Qiao, Yifan Jia, Ling Ye, Zeli Li, Jiahe Ouyang, Haoxian Zhou, Kangxin Zeng, Xuemeng Wang, Yixian Wang, Yang Zhang, Yupeng Zhang, Yizhou Cai, Yutao Hu, Minzhe Zhang, Wenwei Xu, Zhenzhen Wu, Xiaofang Qiu, Li Lin   +19 more
wiley   +1 more source

Rituximab (Mabthera), a new approach for the treatment of rheumatoid arthritis. A systematic review [PDF]

Einstein (São Paulo), 2007
Rituximab is a chimeric monoclonal antibody capable of depleting Bcells expressing CD20. Clinical trials carried out in patients diagnosedwith active, established RA confirm that a single cycle of rituximabgiven as two infusions a week apart, together ...
Eduardo Finger, Morton Aaron Scheinberg
doaj  

Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia. [PDF]

, 1993
B cell chronic lymphocytic leukemia (CLL) is a malignancy of the CD5+ B cells. Prior studies indicated that CLL B cells generally express immunoglobulin (Ig) VH and VL genes with little or no somatic mutations.
Kipps, TJ, Rassenti, LZ
core  

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Journal for ImmunoTherapy of Cancer
Background Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an Fc-silenced, human, CD20×CD3 bispecific antibody that targets CD20-expressing cells via T ...
Dina M Flink, Se Jeong, Gavin Thurston, Rajat Bannerji, Vladimir Jankovic, Nathalie Fiaschi, Max S Topp, Jurriaan Brouwer-Visser, Raquel P Deering, Kamil J Cygan, Darius Scott, Lauren Boucher, Namita T Gupta, Suraj Gupta, Christina Adler, Johannes Duell, Ranjana H Advani, Aafia Chaudhry, Srikanth R Ambati   +18 more
doaj   +1 more source

Thyroid Autoimmunity as a Window to Autoimmunity: An Explanation for Sex Differences in the Prevalence of Thyroid Autoimmunity [PDF]

, 2015
Autoimmune thyroid diseases (AITDs), predominately Graves׳ disease and Hashimoto׳s thyroiditis, comprise the most common autoimmune diseases in humans.
Merrill, Stephen, Mu, Ying
core   +1 more source